60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
15. Mai 2024 13:45 ET | Sixty Degrees Pharmaceuticals
SXTP posts Q1 2024 net product revenues increase of 515% year-over-year to $105.7 thousand in a Q1 earnings report released today.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
22. Januar 2024 07:59 ET | Sixty Degrees Pharmaceuticals
Post-FDA meeting, 60 Degrees Pharma plans pivotal study of tafenoquine in hospitalized babesiosis patients, aiming to start in summer 2024. #biotech #SXTP
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
26. Dezember 2023 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma has received IRB approval for a Phase IIA study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
30. August 2023 07:32 ET | Sixty Degrees Pharmaceuticals
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
15. August 2023 07:31 ET | Sixty Degrees Pharmaceuticals
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering
12. Juli 2023 12:29 ET | Sixty Degrees Pharmaceuticals
WASHINGTON, July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections
26. April 2023 07:34 ET | Sixty Degrees Pharmaceuticals
Patent provides exclusive use through 2040 of tafenoquine for treatment of COVID-19 and other lung infections. Tafenoquine is the active molecule in 60P’s FDA-approved drug for malaria prevention,...